

TRANSGENOMIC INC  
Form 8-K  
January 20, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 14, 2016**

**Transgenomic, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**                            **000-30975**    **91-1789357**  
(State or Other Jurisdiction of    (Commission    (IRS Employer  
Incorporation)                      File Number)    Identification No.)

**12325 Emmet Street, Omaha, NE 68164**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(402) 452-5400**

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 14, 2016, John D. Thompson notified Transgenomic, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) and each committee of the Board that he was a member of, effective immediately. Mr. Thompson served as a member of the Audit Committee of the Board and the Compensation Committee of the Board. Mr. Thompson resigned from the Board for personal reasons. His resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Upon Mr. Thompson’s resignation, Mya Thomae was appointed as a member of the Audit Committee of the Board and the Compensation Committee of the Board.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Transgenomic, Inc.**

By: /s/ Paul Kinnon  
Paul Kinnon  
Chief Executive Officer

Date: January 20, 2016